215: Pathology-Driven Strategies in Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma

Send us Fan Mail Paper Discussed in this Episode: Modern Pathology-Driven Strategies in Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: From Residual Tumor Quantification to Spatial and AI-Based Biomarkers. Annabella Di Mauro, Rossella De Cecio, Saverio Simonelli, et al. Cancers (MDPI) 2026. Episode Summary: In this journal club deep dive, we explore a paradigm-shifting 2026 paper that fundamentally fractures our reliance on traditional radiology in head and neck cancer. We uncover a shocking clinical disconnect where seemingly devastating CT scans mask miraculous microscopic victories. When neoadjuvant immunotherapy unleashes the immune system, why does the tumor often look like it's growing on imaging? And how is pathology stepping out of the shadows to become the ultimate arbiter of biological truth, dictating precise surgical and medical oncology decisions? In This Episode, We Cover: The Trojan Horse of Imaging (Pseudoprogression): Why traditional CT scans are failing us in the immunotherapy era. Immunotherapy causes an influx of T-cells and inflammation that physically expands the tissue, tricking radiologists into diagnosing progressive disease when the cancer is actually being systematically dismantled from the inside out. The New Gold Standard - RVT: Why measuring the "shadow" of the tumor is obsolete. We discuss why pathologists are pivoting away from size and instead strictly quantifying Residual Viable Tumor (RVT) to determine the exact percentage of living, metabolically active carcinoma cells left behind. The "Starry Sky" Phenomenon: Tumors don't shrink like an ice cube melting from the outside in. We discuss how immune cells tunnel into the tumor, shattering it into a discontinuous "starry sky" pattern—scattered, radiologically occult microscopic islands of surviving cancer hidden across a vast sea of therapy-altered stroma. Compartmental Dissociation (The Nodal Force Field): A terrifying clinical reality where a patient can achieve a 100% complete pathological response at the primary mucosal site, but simultaneously harbor highly viable, proliferating cancer in their cervical lymph nodes. We explore how tumors hijack M2 macrophages to build a localized, cytokine-driven "force field" that neutralizes systemic T-cells the second they enter the node. The Future - High-Definition Spatial Biology: How AI-assisted digital pathology and spatial transcriptomics act as the "GPS tracking" or "sports analytics" of the tumor microenvironment. By mapping the exact coordinates of immune and cancer cells, tumor boards can confidently de-escalate toxic post-operative treatments for clear patients, or accurately target specific immunosuppressive resistance niches. Key Takeaway: Traditional imaging measures the volume of the battlefield, not the volume of the remaining enemy . By redefining therapeutic response through the microscopic lens of Residual Viable Tumor and AI-driven spatial biology, pathologists are no longer just staging dead tissue. They are now the central navigators of precision oncology, guiding the real-time escalation and de-escalation of patient care based on the true biological reality of the tumor Support the show Get the "Digital Pathology 101" FREE E-book and join us!

You can listen to 215: Pathology-Driven Strategies in Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma online on Radio and Podcast. Open the player on this page to stream the available audio.

215: Pathology-Driven Strategies in Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma is an episode from Digital Pathology Podcast by Aleksandra Zuraw, DVM, PhD.

This episode is 22:41 long.

This episode was published on Apr 2, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Digital Pathology Podcast when more episodes are available from the podcast feed.